The cardiovascular system in patients with functional and inflammatory bowel diseases
- Authors: Maev IV1, Kazulin AN1, Andreev DN1
-
Affiliations:
- A.I. Evdokimov Moscow state medical dental University, Ministry of health of Russia
- Issue: Vol 90, No 2 (2018)
- Pages: 59-64
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32825
- DOI: https://doi.org/10.26442/terarkh201890259-64
- ID: 32825
Cite item
Full Text
Abstract
Aim. Identification of subclinical and metamanifests state changes of cardiovascular system in patients with functional and inflammatory bowel diseases (IBD) without a background of cardiac pathology. Materials and methods. Was examined 79 patients with colon diseases, 20 patients were diagnosed with irritable bowel syndrome (IBS) with diarrhea, 37 - with undifferentiated colitis (UdC) and 22 patients with ulcerative colitis (UC). As a control group were examined in 50 healthy subjects. All patients received treatment in accordance with international and national guidelines. Prescribed medications had effect on the function of the cardiovascular system. Patients with contacting the hospital and against the onset of remission was performed ultrasound of the heart. Determines the size of the left atrium, heart rate, end-diastolic volume, end-systolic volume, ejection fraction (EF), cardiac index (CI), total peripheral vascular resistance, the presence of right heart failure, blood flow, the area of the right atrium and right ventricle in systole and diastole, and calculated the proportion of contractility of the right atrium and right ventricle. Determined systolic pressure in PA (SPPA), the average pressure in PA (APPA). Results. Clinical manifestations of cardiac syndrome was identified in 75,0% of patients with IBS, 54,1% of patients NK and 68,2% patients with UC. When performing correlation analysis in the patients with UdC and UC was noted the relationship of hemodynamic parameters and disease severity was more pronounced in UC. So, when comparing the duration of the disease and levels of the MLC - r=0,52 and r=0,73 (p<0,05), EF - r=-0,51 and r=-0,71 (p<0,05), CI - r=0,49 and r=0,70 (p<0,05), heart rate - r=0,47, r=0,68 (p<0,05); duration of stay in hospital and the magnitudes of MLC - r=0,54 and r=0,77 (p<0,05), EF - r=-0,51 and r=-0,71 (p<0.05), CI - r=0,55 and r=0,73 (p<0,05), heart rate - r=0,47, r=0,63 (p<0,05). For patients with UC, we noted the presence of correlation when the average frequency of exacerbations per year and the values of the MLC - r=0,53 (p<0,05), EF - r=-0,55 (p<0,05), heart rate: r=0,54 (p<0,05); severity of UC and EF (r=-0,67; p<0,05). A statistically significant correlation of changes in EF and value SPPA and APPA, aggravated by the deepening severity of the disease. So, for IBS - r=-0,46, and r=-0,48 (p<0,05); for NK - r=-0,51 and r=-0,59 (p<0,05); for the UC - r=-0,62, and r=-0,67 (p<0,05). In the analysis of duration of hospitalization, and values SPPA and APPA for patients with IBS - r=0.48 and r=0.46 (p<0,05); with UdC - r=0,50 and r=0,53 (p<0,05); with UC - r=0,59 and r=0,62 (p<0,05). Sick UC was characterized by the greatest dilatation of RA and RV with access from outside the variations of the norms of 90.9 and 68.2 per cent, a significant decrease dRA and dRV. Discovered correlation of the squares of PP and SDL - r=0,48, r=0,54 and r=0,61 (p<0,05); APPA - r=0,50, r=0,56 and r=0,63 (p<0,05); RV areas and levels SPPA - r=0,45, r=0,50 and r=0.52 (p<0,05); and APPA - r=0,46, r=0,47 r=0,53 (p<0,05). When analyzing the values of the squares of the pancreas and MLC - r=0,47 r=0,54 and r=0,61 (p<0,05), levels of EF and dRV - r=0,41, r=0,50 and r=0,56 (p<0,05). Conclusion. Cardiac syndrome in patients with IBS and IBD without a background of cardiac pathology can occur in the form of subclinical or manifested weakly, but persistent changes that may not be recognized, but in the future may complicate the course of the underlying disease, necessitating research to develop tactics to correct them.
Full Text
##article.viewOnOriginalSite##About the authors
I V Maev
A.I. Evdokimov Moscow state medical dental University, Ministry of health of Russiaд.м.н., проф., академик РАН, зав. каф. пропедевтики внутренних болезней и гастроэнтерологии Moscow, Russia
A N Kazulin
A.I. Evdokimov Moscow state medical dental University, Ministry of health of Russia
Email: alexander.kazyulin@yandex.ru
д.м.н., академик РАЕН, проф. каф. пропедевтики внутренних болезней и гастроэнтерологии Moscow, Russia
D N Andreev
A.I. Evdokimov Moscow state medical dental University, Ministry of health of Russiaк.м.н., ассистент каф. пропедевтики внутренних болезней и гастроэнтерологии Moscow, Russia
References
- Воробьев Г.И., Халиф И.Л. Неспецифические воспалительные заболевания кишечника. Москва: Миклош; 2008. 400 с.
- Парфенов А.И. Энтерология. Москва: ООО «Медицинское информационное агентство»; 2009. 880 с.
- Михайлова З.Ф. Системная патология при хронических воспалительных заболеваниях кишечника. Экспериментальная и клиническая гастроэнтерология. 2010;(3):95-9.
- Михайлова З.Ф. Бронхолегочная патология у больных язвенным колитом и болезнью Крона. Автореф. дисс. … докт. мед. наук. Москва; 2011. 43 с. [.
- Rogler G, Scholmerich J. Extraintestinal manifestations of inflammatory bowel disease. Med Clin. 2004;99(3):123-30. doi: 10.1007/s00063-004-1003-2
- Ruisi P, Makaryus J.N, Ruisi M, Makareyus N. Inflammatory Bowel Disease as a Risk Factor for Premature Coronary Artery Disease. J Clin Med Res. 2015;7(4):257-61. doi: 10.14740/jocmr2102w
- Хлынова О.В., Туев А.В., Василец Л.М., Кузнецова Е.С. Заболевания сердечно - сосудистой системы и воспалительные заболевания кишечника: коморбидность или полиморбидность? Пермский медицинский журнал. 2017;(2):94-102.
- Lindhardsen J, Kristensen S.L, Ahlehoff O. Management of Cardiovascular Risk in Patients with Chronic Inflammatory Diseases: Current Evidence and Future Perspectives. Am J Cardiovasc Drugs. 2016;16(1):1-8. doi: 10.1007/s40256-015-0141-4
- Kristensen S.L, Ahlehoff O, Lindhardsen J, Erichsen R, Jensen G.V, Torp-Pedersen C, Nielsen O.H. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death - a Danish nationwide cohort study. PLoS One. 2013;8(2):e56944. doi: 10.1371/journal.pone.0056944
- Yarur A.J, Deshpande A.R, Pechman D.M, Tamariz L, Abreu M.T, Sussman D.A. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol. 2011;106 (4):741-7. doi: 10.1038/ajg.2011.63
- Singh S, Kullo I.J, Pardi D.S, Loftus E.V. Jr. Epidemiology, risk factors and management of cardiovascular diseases in IBD. Nat Rev Gastroenterol Hepatol. 2015;12(1):26-35. doi: 10.1038/nrgastro.2014.202
- Rellecke P, Strauer B. Chronic inflammatory bowel disease and cardiovascular complications. Med Klin (Munich). 2006;101(1):56-60.
- Pattanshetty D.J, Anna K, Gajulapalli R.D, Sappati-Biyyani R.R. Inflammatory Bowel “Cardiac” Disease: Point Prevalence of Atrial Fibrillation in Inflammatory Bowel Disease Population. Saudi J Gastroenterol. 2015;21(5):325-9. doi: 10.4103/1319-3767.166208
- Cioffi U, Giulla M, De Simone M, Paliotti R, Pierini A, Magrini F, Botti F, Contessini-Avesani E. Effects of chronic inflammatory bowel diseases on left ventricular structure and function: a study protocol. BMC Public Health. 2002;2:19. doi: 10.1186/1471-2458-2-19
- Calishkan Z, Gokturk H.S, Caliskan M, Gullu H, Cifci O, Ozgur G.T, Guven A, Selcuk H. Impaired coronary microvascular and left ventricular diastolic function in patients with inflammatory bowel disease. Microvasc Res. 2015;97:25-30. doi: 10.1016/j.mvr.2014.08.003
- Sharma P, Makharia G.K, Ahuja V, Dwivedi S.N, Deepak K.K. Autonomic dysfunctions in patients with inflammatory bowel disease in clinical remission. Dig Dis Sci. 2009;54(4):853-61. doi: 10.1007/s10620-008-0424-6
- Pellissier S, Dantzer C, Canini F, Mathieu N, Bonaz D. Psychological adjustment and autonomic disturbances in inflammatory bowel diseases and irritable bowel syndrome. Psychoneuroendocrinology. 2010;35(5):653-62. doi: 10.1016/j.psyneuen.2009.10.004
- Vizzardi E, Sciatti E, Bonadei T, Ricci C, Lanzarotto F, Lanzini A, Metra M. Subclinical cardiac involvement in Crohn's disease and ulcerative colitis: an echocardiographic case - control study. Panminerva Med. 2016;58(2):115-20.
- Truelove S.C, Witts L.J. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J. 1955 Oct 29;2(4947):1041-8.
- Drossman D.A, Hasler W.L. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016;150(6):1257-61. doi: 10.1053/j.gastro.2016.03.035
- Самсонов А.А., Андреев Д.Н., Дичева Д.Т. Синдром раздраженного кишечника с позиций современной гастроэнтеорлогии. Фарматека. 2014;18:7-13.
- Андреев Д.Н., Заборовский А.В., Трухманов А.С., Маев И.В., Ивашкин В.Т. Эволюция представлений о функциональных заболеваниях желудочно - кишечного тракта в свете Римских критериев IV пересмотра (2016 г.). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(1):4-11 gii, Koloproktologii. 2017;27(1):4-11 (In Russ.)]. doi: 10.22416/1382-4376-2017-27-1-4-11
- Маев И.В., Самсонов А.А., Яшина А.В., Казюлин А.Н., Шестаков В.А. Новые возможности в лечении синдрома раздраженного кишечника: эффективный подход и коррекция качества жизни. Фарматека. 2016;15:12-8.
- Казюлин А.Н. Колофорт: механизм действия и возможности патогенетической терапии заболеваний желудочно - кишечного тракта. Гастроэнтерология Санкт-Петербурга. 2016;(1-2):19-23.
- Казюлин А.Н. Особенности состояния сердечно - сосудистой системы у больных с заболеваниями органов пищеварения. Автореф. дисс.. докт. мед. наук. Москва; 2000. 47 с.
- Deepak J.P, Rama D.G, Kiran A, Raja S. Sappati B. Prevalence of QT interval prolongation in inflammatory bowel disease. Turk J Gastroenterol. 2016;27:136-42. doi: 10.5152/tjg.2015.150349
- Caviglia R, Boskoski I, Cicala M. Long - term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opin Drug Saf. 2008;7:617-32. doi: 10.1517/14740338.7.5.617
- Mudter J, Neurath M.F. IL-6 Signaling in Inflammatory Bowel Disease: Pathophysiological Role and Clinical Relevance. Inflamm Bowel Dis. 2007;13:1016-23. doi: 10.1002/ibd.20148
- Cibor D, Domagala-Rodacka R, Rodacki T, Jurczyszen A, Macg T, Owczarek D. Endothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implications. World J Gastroenterol. 2016;22(3):1067-77. doi: 10.3748/wjg.v22.i3.1067